Cardiac Resynchronization Therapy Market

USD 7.7 billion in 2026 to USD 16.5 billion by 2036 at 7.9% CAGR.

• The market reached USD 7.1 billion in 2025.
• Demand is projected to rise from USD 7.7 billion in 2026 to USD 16.5 billion by 2036.
• The market is forecast at a 7.9% CAGR from 2026 to 2036 as heart failure programs and hospital rhythm services prioritize CRT-D and CRT-P implantation for eligible patients.

What are the defining numbers behind Cardiac Resynchronization Therapy Market growth?

USD 8.8 billion absolute opportunity by 2036, led by CRT Defibrillator, Hospital end use and Heart Failure Treatment.

• Demand Drivers in the Market
  • Electrophysiology teams need reliable CRT-D systems because heart failure patients require both resynchronization and defibrillation support in one implant.
  • Hospital cardiac units need predictable battery and lead performance so device replacement planning does not disrupt chronic care.
  • Clinicians need clear eligibility documentation as CRT implantation depends on ejection fraction, rhythm status and symptom class.
  • Patients need follow-up systems that support device checks after implantation without creating avoidable clinic visits.
• Key Segments Analyzed
  • By Product: CRT Defibrillator is projected to hold 61.8% share in 2026 owing to combined pacing and shock therapy use.
  • By End Use: Hospital is expected to account for 63.8% share in 2026 because implantation requires electrophysiology infrastructure.
  • By Application: Heart Failure Treatment is anticipated to capture 68.4% share in 2026 due to guideline-linked CRT candidacy.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha is Principal Consultant at Fact.MR. He states, “CRT suppliers are judged on clinical reliability after implant and not only on generator features. Adoption is expected to depend on fewer device advisories, documented lead support and practical remote follow-up. Hospitals are likely to favor portfolios that connect therapy delivery with clear service coverage.”
• Strategic Implications
  • Device manufacturers should keep battery sourcing, lead reliability and software updates visible to hospital review teams.
  • Hospitals should align CRT candidate screening with heart failure clinics and electrophysiology scheduling capacity.
  • Distributors should focus training on CRT-P and CRT-D differences so procurement teams avoid poor product matching.
  • Investors should separate direct CRT device exposure from broader cardiac monitoring and general implantable-device portfolios.

The USA is expected to record 8.3% CAGR through 2036 supported by large rhythm-device programs and FDA-reviewed CRT-D supply activity. Japan is projected to post 8.1% as population aging sustains heart failure treatment demand. The UK is anticipated to advance at 7.8% owing to national rhythm-management audit coverage. France is estimated to reach 7.2% due to a large heart failure population. South Korea is forecast to record 7.1% as aging and reimbursement rules shape candidate selection. Italy is expected to post 6.3% as hospital capacity and older-age care needs pull in opposite directions.

CRT Defibrillator leads Product at 61.8%; Hospital leads End Use at 63.8%; Heart Failure Treatment leads Application at 68.4%.

Which product dominates?

CRT Defibrillator holds 61.8% share in 2026.

CRT Defibrillator is projected to lead Product owing to combined resynchronization and defibrillation support for patients at arrhythmic risk. Single chamber, dual chamber and biventricular CRT defibrillators address different pacing needs. CRT pacemakers remain relevant when shock therapy is not required. FDA PMA supplement P010031S907 in December 2025 added an alternate lithium supplier for Medtronic ICD and CRT-D batteries. FDA approved Boston Scientific RESONATE CRT-D updates on April 21, 2026.

What leads the End Use segment?

Hospital holds 63.8% share in 2026.

Hospital is expected to lead End Use since CRT implantation requires electrophysiology labs, imaging support and trained follow-up teams. Public hospitals support procedure volume where national reimbursement and audit systems are established. Private hospitals contribute through planned cardiac care and shorter procedure pathways. Cardiac centers and electrophysiology centers remain valuable for complex lead placement and revisions. NHS England Digital reported 227 providers and over 2.6 million registry devices by December 2025.

How does Application shape demand?

Heart Failure Treatment holds 68.4% share in 2026.

Heart Failure Treatment is anticipated to lead Application since CRT directly targets ventricular dyssynchrony in selected patients. Systolic heart failure creates the clearest implant pathway because low ejection fraction is central to eligibility. Arrhythmia management supports CRT-D use when defibrillation protection is needed. Post-surgical cardiac care and congenital heart disease remain narrower uses that require specialist review.

Heart failure treatment need drives it; strict eligibility and device reliability checks restrain it.

Drivers Impact Analysis

• RT-D use in eligible patients: CRT-D systems carry value where resynchronization and shock therapy are both needed.
• Hospital electrophysiology capacity: CRT implantation depends on procedure rooms and specialists who can manage lead placement.
• Remote follow-up workflow: Remote checks help clinicians review alerts and device status between visits.
• Guideline-linked candidate selection: CRT use depends on ejection fraction, QRS duration and symptom status.

Opportunity Impact Analysis

• MRI-conditional CRT systems: Cardiac patients often need later imaging, so MRI conditions affect device choice. Hospitals are expected to favor CRT portfolios that define scanning conditions clearly. The opportunity is stronger where imaging access is routine and device records are easy to verify.
• Device data and remote checks: CRT follow-up creates steady data review work for device clinics. Procurement teams are expected to compare software support along with generator features.
• Public hospital replacement pathways: Battery replacement and lead assessment create repeat demand after first implantation. Public hospitals are expected to use procedure reporting when replacement scheduling becomes visible. Public systems are expected to standardize device review where national procedure reporting remains active.
• Lead design and battery reliability: Reliability remains a purchasing test because lead or battery issues require clinical action. Medtronic’s September 2025 OmniaSecure release said the LEADR LBBAP trial met safety and efficacy objectives at three months. Suppliers are expected to prove performance through post-market evidence.

Restraints Impact Analysis

• Strict eligibility criteria: CRT is not a broad heart failure implant. HIRA’s February 2025 CRT-P criteria include ejection-fraction and pacing-percentage thresholds. These gates protect outcomes but slow conversion from diagnosis to procedure.
• Lead placement complexity: Left ventricular lead placement can extend procedure time when venous anatomy is difficult. Failed placement raises the need for revision or alternative pacing strategies. Smaller centers are expected to refer complex cases to specialist hospitals.
• Reimbursement documentation: Coverage rules require evidence that patients meet clinical thresholds. Weak documentation can delay approval even when clinical need is clear.

• The country comparison spans 2.0 percentage points and forms three practical growth bands across the forecast period.
• The USA remains 0.2 percentage point above Japan through device review activity and hospital rhythm-care depth.
• Japan remains 0.3 percentage point above the UK as population aging supports CRT candidate pools.
• The UK remains 0.6 percentage point above France owing to national rhythm-management audit coverage.
• France remains 0.1 percentage point above South Korea as heart failure detection programs expand clinical attention.
• South Korea remains 0.8 percentage point above Italy as aging growth offsets tighter reimbursement gates.
• Italy closes the displayed range because hospital recovery and demographic pressure move at different speeds.

Comparable CAGRs create different entry conditions because CRT demand depends on cardiology capacity and reimbursement rules. Follow-up systems and device reliability then shape adoption paths. Full report coverage includes North America, Europe, East Asia, South Asia and Pacific, Latin America, and Middle East and Africa.

What supports USA adoption?

8.3% CAGR, supported by hospital rhythm care and FDA-reviewed CRT-D supply updates.

The USA’s growth reflects a large cardiac care network where hospitals can manage implantation, generator replacement and follow-up. CRT-D adoption remains supported where heart failure and sudden cardiac death risks are managed together, while device corrections, payer documentation and lead-placement complexity can delay uptake.

How is Japan developing demand?

8.1% CAGR, led by population aging and specialist cardiac care capacity.

Japan’s growth is supported by an aging population and hospital systems equipped for electrophysiology, imaging and device follow-up. The Statistics Bureau of Japan reported 36.19 million people aged 65 and over in September 2025, equal to 29.4% of the population. Providers value MRI conditions, device size and reliability, while specialist-center concentration and replacement planning can limit broader access.

What is driving UK growth from 2026 to 2036?

7.8% CAGR, backed by national rhythm-device audit coverage and heart disease burden.

The UK’s growth reflects structured rhythm-device auditing and referral links between heart failure and electrophysiology services. GOV.UK reported around 1.9 million people in England with a GP diagnosis of coronary heart disease in the year ending March 2025. Audit coverage supports procedure quality comparison, while waiting lists, incomplete device data and uneven technology uptake can slow implantation.

How does France perform?

7.2% CAGR, supported by heart failure prevalence and an aging population.

France’s growth is supported by a large heart failure population and specialist cardiology services that manage imaging, implantation and follow-up. Assurance Maladie reported in September 2025 that heart failure affects 1.5 million people in France. Awareness programs can improve referral, while delayed diagnosis and regional access gaps may keep suitable patients outside timely CRT evaluation.

How is South Korea scaling demand?

7.1% CAGR, shaped by super-aged demographics and reimbursement screening.

South Korea’s growth reflects an aging population and tertiary hospitals where heart failure and arrhythmia teams can coordinate CRT-D implantation. Statistics Korea reported that people aged 65 and over represented 20.3% of the population in 2025. Remote follow-up supports long-term monitoring, while reimbursement screening, documentation thresholds and specialist-hospital concentration can restrict access.

What supports Italy adoption?

6.3% CAGR, supported by older-age demand but restrained by hospital recovery pressure.

Italy’s growth is supported by an aging population and specialist cardiology centers that manage lead placement, programming and replacement planning. ISTAT reported 14.821 million Italians aged 65 and over on 1 January 2026, equal to 25.1% of the population. Hospital recovery pressure, regional access differences and public-system scheduling can still delay CRT implantation.

Medtronic, Boston Scientific, Abbott Laboratories, BIOTRONIK and MicroPort CRM (MicroPort Scientific Corporation) form the verified provider set.

Medtronic and Boston Scientific show direct CRT-D regulatory activity. Abbott Laboratories maintains CRT-D participation through its cardiac rhythm management portfolio. BIOTRONIK maintains official CRT defibrillator and CRT pacemaker systems. MicroPort CRM (MicroPort Scientific Corporation) supports CRT participation through its CRM portfolio. BIOTRONIK announced U.S. FDA approval of Acticor Sky and Rivacor Sky ICD/CRT-D systems in April 2026. MicroPort CRM expanded SmartView Connect across Europe and Australia in December 2025 for compatible CRT-D remote monitoring.

Key companies include Medtronic and Boston Scientific alongside Abbott Laboratories, BIOTRONIK and MicroPort CRM (MicroPort Scientific Corporation).

• Medtronic
• Boston Scientific
• Abbott Laboratories
• BIOTRONIK
• MicroPort CRM (MicroPort Scientific Corporation)

• Assurance Maladie. (2025, September 22). L’insuffisance cardiaque, une campagne qui touche au cœur.
• Tsai, B. (2026, July 2). Provisional data: U.S. death rate fell to a record low in 2025. National Center for Health Statistics, Centers for Disease Control and Prevention.
• U.S. Food and Drug Administration. (2025, December 3). Premarket approval supplement: Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, and Crome MRI CRT-D (P010031/S907) [Database record].
• U.S. Food and Drug Administration. (2026, May 7). Pacemaker correction: Boston Scientific issues correction for ACCOLADE pacemakers and CRT-Ps.
• Institut national de la statistique et des études économiques. (2026, January 13). Bilan démographique 2025.
• Medtronic. (2025, September 2). Compelling data at ESC Congress 2025 reinforce safety and performance of the Medtronic OmniaSecure™ defibrillation lead, including in the left bundle branch area.
• National Institute for Cardiovascular Outcomes Research. (2026, June 18). National Audit of Cardiac Rhythm Management: 2026 interim report.

• The report provides strategic intelligence on the Cardiac Resynchronization Therapy Market across Product, End Use and Application choices that shape hospital implant programs.
• Segment analysis covers CRT Defibrillator, Hospital and Heart Failure Treatment as the share leaders within the 2026 market.
• Country outlook evaluates the USA and Japan alongside the UK and France. South Korea and Italy complete the listed growth comparison.
• Competitive analysis profiles Medtronic, Boston Scientific, Abbott Laboratories, BIOTRONIK and MicroPort CRM (MicroPort Scientific Corporation).
• Device assessment covers CRT-D and CRT-P use. It also reviews eligibility criteria, replacement demand, hospital follow-up and device reliability concerns.

Cardiac resynchronization therapy systems are used in heart failure patients when pacing both ventricles can improve coordination. The market belongs to broader cardiac rhythm management devices and overlaps with cardiac pacemaker systems when therapy does not require defibrillation.

The market covers CRT-D and CRT-P generators, related lead configurations, hospital implantation activity and follow-up services. It also connects to MRI safe implantable defibrillator devices where scanning conditions affect purchasing. Adjacent device categories such as wireless pacemaker leads and implantable medical devices are considered only when they affect CRT selection.

What is included in the scope?

The scope includes CRT defibrillators and CRT pacemakers. It covers hospital implantation, heart failure treatment and arrhythmia management. Post-surgical cardiac care is included where CRT supports recovery. Country-level demand is linked to United States cardiac rhythm management devices and United Kingdom cardiac rhythm management devices where local device care pathways influence adoption.

What is excluded from the scope?

General patient monitoring and unrelated surgical products remain outside the scope unless they directly support CRT implantation or follow-up. Broader cardiovascular monitoring devices, cardiac prosthetic devices and heart pump devices are excluded when they do not provide CRT pacing or CRT-D therapy.

How Was the Analysis Built?

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries and 20+ industry interviews.

• Primary Research: Primary research includes discussions with device manufacturers, hospital procurement teams, electrophysiology specialists and distributors. These discussions examine supplier selection, implantation barriers and follow-up needs.
• Desk Research: Desk research covers government statistics and regulator publications. It also reviews audit data, company pages, product approvals and reimbursement criteria. Every source used in the analysis is documented in the bibliography.
• Market Sizing and Forecasting: Market estimates combine historical performance and implantable-device demand indicators. The model also uses segment shares, country growth, hospital capacity, reimbursement rules and barriers to expansion.
• Data Validation and Update Cycle: Findings are validated by comparing primary interviews with public data, company activity, regulatory updates, recall records and new device launches. Regular updates review approvals, advisories, procurement trends and shifts in clinical use.

• By Product:

  • CRT Defibrillator
    • Single Chamber CRT Defibrillator
    • Dual Chamber CRT Defibrillator
  • Biventricular CRT Defibrillator
    • CRT Pacemaker
    • Single Lead CRT Pacemaker
  • Dual Lead CRT Pacemaker
    • Biventricular CRT Pacemaker

• By End Use:

  • Hospital
    • Public Hospitals
    • Private Hospitals
  • Teaching Hospitals
    • Cardiac Center
    • Electrophysiology Centers
  • Heart Failure Centers
    • Ambulatory Cardiac Centers
    • Other End Users
  • Diagnostic Centers
    • Ambulatory Surgical Centers
    • Specialty Clinics

• By Application:

  • Heart Failure Treatment
    • Systolic Heart Failure
    • Diastolic Heart Failure
  • Arrhythmia Management
    • Atrial Fibrillation Management
    • Ventricular Arrhythmia Control
  • Post Surgical Cardiac Care
    • Post Cardiac Surgery Recovery
    • Post Implant Monitoring
  • Congenital Heart Disease
    • Pediatric CRT Applications
    • Structural Heart Disorders

• By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia and Pacific
  • Middle East & Africa